ARCHIVES

DCPC Board Defers Two Concepts More Approvals Listed

This article is from The Cancer Letter archive.

Vol. 10 No. 40 | October 19, 1984

Download PDF Visit The Full Archive

Related Articles

Gleevec Produces 59% Response Rate In Gastrointestinal Stromal Tumors

May 25, 2001

Afinitor and Exemestane More Than Doubles PFS, Reduces Progression Risk by 57 Percent

September 30, 2011

NCI Says More Phase Trials Needed In Cancer Prevention, Nutrition

April 18, 1986

Six Patients Apparently responded To Laetrile, NCI Review Finds; DCT Considers Clinical Trials

September 8, 1978

In Congress: Senate Bill Offers 13% Increase For NCI; house Provides 9%

October 8, 1999

FDA Begins To Examine Its Role In Allowing Misleading Consumer Advertising.

May 18, 2007